Nervous Disorder TRIZ Cases

A fatty acid vesicle-based emulsion encapsulates essential amino acids in a liquid composition.

Segmented peptide vaccines induce specific immunity against alpha-synuclein oligomers without triggering autoimmunity.

Soluble CEACAM8 binds CEACAM1 on granulocytes to prevent apoptosis, resolving non-selective targeting issues in autoimmune treatments.

Malate salts of a specific cyclopropane dicarboxamide compound improve solubility and stability to treat cancers involving Ret, c-Met, and VEGFR2 kinases.

Increasing ALZ-801 dosage beyond 530 mg daily overcomes limited efficacy in moderate to severe Alzheimer's, improving cognitive function and quality of life.

Pharmacological chaperones bind to gangliosidases and sialidases to increase enzyme activity.

Quantifying microRNA expression via oligodeoxynucleotide probes enables non-invasive traumatic brain injury diagnosis without complex invasive procedures.

A one-armed anti-human NR1 antibody binds to NMDAR receptors to block pathogenic interactions.

Engineered attenuated Salmonella typhimurium bacteria deliver pharmaceutical agents to infarcted myocardium and brain tissue.

Compounds inhibit prolyl hydroxylase to stabilize HIF-1α, resolving insufficient activation of hypoxia response genes.

Novel heterocyclic FTO inhibitors overcome reduced activity from conventional substitutions to effectively manage obesity.

Segmented chimeric proteins deliver IL-2 across the blood-brain barrier to expand regulatory T cells locally, avoiding systemic immunosuppression.

Tau-specific antisense oligonucleotides modulate Tau mRNA splicing and protein expression to address underlying pathogenesis of neurodegenerative diseases.

Replacing high potassium with adenosine agonists and lidocaine mitigates ischemia-reperfusion injury while maintaining reliable cardioplegic arrest.

Diterpene compounds derived from Daphne genkwa activate Nurr1 and suppress microglial inflammation to address causal mechanisms of Parkinson's disease.

Light-activated proteins intercept action potentials to resolve weak photocurrent limitations in optogenetic inhibition.

NSC74429 compounds reduce organ injury by inhibiting pAKT473 levels, addressing inadequate treatments for ischemic events.

A human hepatocyte growth factor mutant with a basic side chain at position 130 increases receptor binding affinity.

Replacing hazardous Raney nickel hydrogenation with a mild NaBH4-ZnCl2 reducing system eliminates safety hazards and complex column chromatography.

A Notch3 extracellular domain fused to an antibody Fc portion binds ligands to block signaling.

Attaching glycosyl groups at specific positions reduces adverse side effects while maintaining therapeutic efficacy.

Chiral levetiracetam derivatives enable high-affinity antibody binding, replacing slow chromatography with rapid immunoassays.

Protease-cleavable linkers mask immune binding regions until tumor proximity, preventing off-target T cell activation and improving therapeutic safety.

A dual-binding ligand co-internalizes with tau assemblies and engages TRIM21 to trigger intracellular proteasomal degradation.

Diels-Alder adducts of chalcone and prenylphenyl moieties modulate cannabinoid receptors to regulate appetite.

Targeting the NCCa-ATP channel disrupts the tumor-brain barrier, enhancing therapeutic agent delivery to brain metastases.

Polyamine-conjugated immunogens generate antibodies that selectively detect clozapine in biological fluids.

Reducing Ikaros transcription factors expands hematopoietic stem cells while preserving multi-potency and functional potential.

Th2-biased adjuvants direct antibody production against amyloid plaques while suppressing harmful Th1 cellular inflammation.

Algal proteoglycan extract inhibits pancreatic carcinoma cell proliferation, addressing poor survival rates in pancreatic cancer treatment.

Adeno-associated viral vectors deliver glucosylceramidase beta genes to restore enzyme activity, reducing substrate accumulation and alpha-synuclein pathology.

Administering RANTES and eotaxin inhibitors reduces T cell infiltration and glial activation to protect dopaminergic neurons from nigrostriatal degeneration.

Hybrid galanthamine derivatives combine acetylcholinesterase inhibition with gamma-secretase targeting in a single molecular structure.

Covalent binding to Cysteine86 overcomes moderate potency and narrow structure-activity profiles of prior necrosulfonamide inhibitors.

Antibodies bind transthyretin to stabilize non-toxic conformations, preventing pathogenic aggregation.

Replacing ethyl bromoacetate with cyanoacetic acid eliminates purification bottlenecks, achieving over 97% conversion and 99% purity in agomelatine synthesis.

Purifying batches to remove 10-Br-carbamazepine impurity prevents visible precipitate formation in the injectable composition.

Drug combination reduces endoplasmic reticulum stress while promoting pro-regenerative phenotypes in peripheral nerve injuries.

Antibodies targeting the phosphorylated serine 396 residue selectively deplete hyperphosphorylated tau while sparing non-pathological species.

Myeloperoxidase inhibitors block oxidative pathways to treat multiple system atrophy by reducing neuroinflammation and preventing neuronal loss.

A polymeric substrate binds nicotine via ion exchange to enable controlled release kinetics without polyol additives.

Piperidinyl-3-(aryloxy)propanamides modulate somatostatin receptor 4 activity through defined structural variations.

Antibodies targeting specific phospho-epitopes clear pathological tau aggregates while preserving normal protein function.

Self-assembling peptide compositions form stable hydrogel barriers that resist fluid interference and bleeding during surgery, preventing adhesion formation.

Segments enzyme replacement into intravenous and subcutaneous routes to reduce hospital visit frequency while maintaining therapeutic efficacy.

Modulating the G3BP2-Tau protein interaction inhibits tau aggregation, addressing limited treatment effectiveness caused by unclear disease mechanisms.

Buccal formulations bypass gastric degradation to deliver drugs rapidly, reducing infection risks from injections.